Ovid therapeutics inc. (OVID)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]
Subsidiary Sale Of Stock [Line Items]
Cash flows from operating activities:
Net loss

-60,461

-51,979

-64,806

-22,414

-13,160

Adjustments to reconcile net loss to cash used in operating activities:
Non-cash research and development expense

-

-

25,861

-

4,011

Common stock issuance for separation agreement

-

-

-

-

381

Stock-based compensation expense

5,205

7,063

6,397

3,641

1,457

Depreciation and amortization expense

255

141

80

56

11

Loss on disposal of intangible assets

-

-4

-

-

-

Change in accrued interest and accretion of discount on short-term investments

-29

-1

-

-

-

Change in operating assets and liabilities:
Prepaid expenses and other current assets

-224

1,305

793

-58

279

Deferred transaction costs

-

-

229

-229

-

Security deposit

-13

-33

-36

-362

-38

Related party receivable

531

-

-

-

-

Long-term prepaid expenses

-2,438

2,192

604

-

-

Other assets

-

-

-

28

-

Accounts payable

-653

1,649

1,076

186

591

Accrued expenses

2,177

1,093

1,118

1,238

1,608

Related party payable

297

-

-

-

-

Due from/ to related parties

-

-

-7

-50

69

Net cash used in operating activities

-51,090

-45,558

-31,469

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-17,801

-5,485

Purchases of short-term investments

34,797

50,011

-

-

-

Proceeds from maturities of short-term investments

5,000

45,000

-

-

-

Purchase of property and equipment

57

33

38

30

32

Software development and other assets

186

318

-

-

-

Software development and other assets

-

-

8

158

24

Net cash provided by (used in) investing activities

-30,041

-5,363

-47

-

-

Cash flows from financing activities:
Proceeds from February Offering, net of offering expenses

64,120

-

-

-

-

Proceeds from employee stock purchase plan

131

174

-

-

-

Net cash used in investing activities

-

-

-

-188

-56

Proceeds from initial public offering, net of offering expenses

-

-

69,750

-

-

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

70,639

Payments for transaction costs

-

-

3,073

13

-

Proceeds from exercise of options

-

111

27

-

-

Net cash provided by financing activities

86,539

286

66,703

-

-

Net (decrease) increase in cash and cash equivalents

5,407

-50,635

-

-

-

Non-cash investing and financing activities:
Offering costs in accrued expenses and accounts payable

69

-

-

-

-

Software development and other costs in accrued expenses and accounts payable

164

60

-

-

-

Purchase of property and equipment in accounts payable

-

19

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-13

70,639

Net increase (decrease) in cash and cash equivalents

-

-

35,185

-18,004

65,097

ATM [Member]
Proceeds from February Offering, net of offering expenses

22,286

-

-

-

-